Ming S. Shi

209 Tongshan Road
Xuzhou, 221004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis.

Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis.

Journal: BMC medicine

Published: February 07, 2026

Neutralizing LFA-1 alleviates acute lung injury by diminishing pulmonary retention of CAR-T cells.

Neutralizing LFA-1 alleviates acute lung injury by diminishing pulmonary retention of CAR-T cells.

Journal: Pharmacological research

Published: February 02, 2026

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

Journal: Science advances

Published: January 02, 2026

CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells.

CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells.

Journal: Theranostics

Published: September 28, 2025

Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial.

Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial.

Journal: EClinicalMedicine

Published: August 06, 2025

Nuclear PD-L1 drives IFN-γ-promoted lung metastasis of triple-negative breast cancer via POLR2A-mediated transcriptional activation of LY6E.

Nuclear PD-L1 drives IFN-γ-promoted lung metastasis of triple-negative breast cancer via POLR2A-mediated transcriptional activation of LY6E.

Journal: Breast cancer research : BCR

Published: July 17, 2025

Development of a DNA Aptamer-Based Approach to Noninvasively Image CAR-T Cells In Vivo and Traceless Enrichment In Vitro.

Development of a DNA Aptamer-Based Approach to Noninvasively Image CAR-T Cells In Vivo and Traceless Enrichment In Vitro.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 14, 2025

EF1α, rather than CMV promoter, is suitable for luciferase tag expression in target cells for in vitro cytotoxicity assays of CAR-T cells.

EF1α, rather than CMV promoter, is suitable for luciferase tag expression in target cells for in vitro cytotoxicity assays of CAR-T cells.

Journal: Molecular therapy. Methods & clinical development

Published: March 17, 2025

Advances in CAR optimization strategies based on CD28.

Advances in CAR optimization strategies based on CD28.

Journal: Frontiers in immunology

Published: December 20, 2024

Developing safe and efficient CGBE editor based on Cas-embedding strategy.

Developing safe and efficient CGBE editor based on Cas-embedding strategy.

Journal: Synthetic and systems biotechnology

Published: November 23, 2024

Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.

Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.

Journal: International urology and nephrology

Published: November 20, 2024

LILRB4 as a novel immunotherapeutic target for multiple diseases.

LILRB4 as a novel immunotherapeutic target for multiple diseases.

Journal: Biochemical pharmacology

Published: October 25, 2024

Showing 1-12 of 108

Last Updated: 09/26/2026